B7-H3 ADC

Hong Kong, August 21, 2026 Akeso, Inc. has announced that its investigational B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received...

ROCKVILLE, MD, July 23, 2026 MacroGenics, Inc. announced a significant clinical update from its ongoing Phase 1 study of...